West Pharmaceutical Services Stock Book Value Per Share

WST Stock

USD 228.68 1.17 0.51%

West Pharmaceutical Services fundamentals help investors to digest information that contributes to West Pharmaceutical's financial success or failures. It also enables traders to predict the movement of West Stock. The fundamental analysis module provides a way to measure West Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to West Pharmaceutical stock.

	Last Reported	Projected for Next Year
Book Value Per Share	36.74	38.58
Tangible Book Value Per Share	35.14	36.90

Book Value Per Share is likely to gain to 38.58 in 2025. Tangible Book Value Per Share is likely to gain to 36.90 in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

West Pharmaceutical Services Company Book Value Per Share Analysis

West Pharmaceutical's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Book Value per Share

Common Equity

Average Shares

More About Book Value Per Share | All Equity Analysis

Current West Pharmaceutical Book Value Per Share

37.10 X

Most of West Pharmaceutical's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, West Pharmaceutical Services is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

West Book Value Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for West Pharmaceutical is extremely important. It helps to project a fair market value of West Stock properly, considering its historical fundamentals such as Book Value Per Share. Since West Pharmaceutical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of West Pharmaceutical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of West Pharmaceutical's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Common Stock	Long Term Debt	Good Will	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Investments	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Accumulated Depreciation	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	-0.78	0.95	0.98	0.78	0.97	0.34	-0.43	0.98	0.57	-0.46	0.47	-0.87	0.96	0.18	0.88	0.95	-0.62	0.52	0.65	0.85	-0.93	0.59	0.88	0.92	0.9	-0.5
Total Stockholder Equity	0.98		-0.84	0.97	0.99	0.69	0.98	0.33	-0.56	0.97	0.58	-0.58	0.36	-0.92	0.96	0.08	0.87	0.98	-0.7	0.59	0.64	0.86	-0.96	0.59	0.9	0.94	0.92	-0.51
Net Debt	-0.78	-0.84		-0.73	-0.8	-0.45	-0.89	-0.37	0.65	-0.78	-0.52	0.73	-0.08	0.87	-0.67	0.07	-0.76	-0.78	0.67	-0.58	-0.64	-0.86	0.91	-0.25	-0.85	-0.86	-0.92	0.1
Retained Earnings	0.95	0.97	-0.73		0.97	0.68	0.9	0.26	-0.6	0.93	0.46	-0.56	0.26	-0.92	0.96	0.1	0.86	0.99	-0.63	0.48	0.63	0.77	-0.89	0.74	0.88	0.93	0.86	-0.68
Net Receivables	0.98	0.99	-0.8	0.97		0.73	0.97	0.26	-0.54	0.98	0.56	-0.51	0.38	-0.91	0.97	0.14	0.89	0.98	-0.67	0.57	0.66	0.86	-0.96	0.58	0.9	0.92	0.9	-0.56
Total Liab	0.78	0.69	-0.45	0.68	0.73		0.74	0.15	0.02	0.75	0.19	0.03	0.5	-0.6	0.68	0.68	0.79	0.66	-0.03	0.01	0.75	0.7	-0.61	0.45	0.69	0.72	0.71	-0.38
Total Current Assets	0.97	0.98	-0.89	0.9	0.97	0.74		0.36	-0.47	0.96	0.58	-0.53	0.4	-0.9	0.9	0.16	0.87	0.92	-0.64	0.55	0.69	0.9	-0.97	0.47	0.91	0.94	0.96	-0.35
Short Term Debt	0.34	0.33	-0.37	0.26	0.26	0.15	0.36		-0.08	0.32	0.17	-0.51	0.22	-0.31	0.24	-0.07	0.13	0.23	-0.27	0.17	0.21	0.23	-0.31	0.31	0.27	0.35	0.31	0.15
Intangible Assets	-0.43	-0.56	0.65	-0.6	-0.54	0.02	-0.47	-0.08		-0.45	-0.2	0.83	0.47	0.73	-0.46	0.42	-0.52	-0.65	0.63	-0.5	-0.35	-0.48	0.59	-0.41	-0.57	-0.59	-0.55	0.44
Accounts Payable	0.98	0.97	-0.78	0.93	0.98	0.75	0.96	0.32	-0.45		0.62	-0.48	0.48	-0.85	0.96	0.13	0.87	0.94	-0.67	0.61	0.65	0.87	-0.95	0.55	0.87	0.88	0.86	-0.49
Common Stock	0.57	0.58	-0.52	0.46	0.56	0.19	0.58	0.17	-0.2	0.62		-0.29	0.58	-0.35	0.62	-0.23	0.35	0.48	-0.77	0.85	0.13	0.55	-0.64	0.08	0.48	0.4	0.39	0.0
Long Term Debt	-0.46	-0.58	0.73	-0.56	-0.51	0.03	-0.53	-0.51	0.83	-0.48	-0.29		0.27	0.7	-0.43	0.49	-0.45	-0.59	0.68	-0.53	-0.33	-0.5	0.63	-0.41	-0.56	-0.6	-0.57	0.18
Good Will	0.47	0.36	-0.08	0.26	0.38	0.5	0.4	0.22	0.47	0.48	0.58	0.27		-0.04	0.49	0.34	0.16	0.22	-0.22	0.32	0.07	0.27	-0.34	0.02	0.18	0.17	0.18	0.0
Treasury Stock	-0.87	-0.92	0.87	-0.92	-0.91	-0.6	-0.9	-0.31	0.73	-0.85	-0.35	0.7	-0.04		-0.82	-0.09	-0.86	-0.95	0.58	-0.43	-0.74	-0.83	0.89	-0.57	-0.93	-0.96	-0.94	0.48
Property Plant Equipment	0.96	0.96	-0.67	0.96	0.97	0.68	0.9	0.24	-0.46	0.96	0.62	-0.43	0.49	-0.82		0.1	0.79	0.95	-0.7	0.6	0.53	0.75	-0.9	0.62	0.81	0.84	0.79	-0.63
Current Deferred Revenue	0.18	0.08	0.07	0.1	0.14	0.68	0.16	-0.07	0.42	0.13	-0.23	0.49	0.34	-0.09	0.1		0.18	0.07	0.57	-0.52	0.55	0.12	0.01	0.06	0.2	0.2	0.2	-0.02
Short Term Investments	0.88	0.87	-0.76	0.86	0.89	0.79	0.87	0.13	-0.52	0.87	0.35	-0.45	0.16	-0.86	0.79	0.18		0.89	-0.45	0.41	0.74	0.93	-0.86	0.51	0.88	0.89	0.88	-0.5
Net Tangible Assets	0.95	0.98	-0.78	0.99	0.98	0.66	0.92	0.23	-0.65	0.94	0.48	-0.59	0.22	-0.95	0.95	0.07	0.89		-0.66	0.53	0.65	0.82	-0.92	0.67	0.9	0.93	0.89	-0.64
Long Term Debt Total	-0.62	-0.7	0.67	-0.63	-0.67	-0.03	-0.64	-0.27	0.63	-0.67	-0.77	0.68	-0.22	0.58	-0.7	0.57	-0.45	-0.66		-0.91	-0.1	-0.55	0.75	-0.29	-0.55	-0.53	-0.53	0.28
Capital Surpluse	0.52	0.59	-0.58	0.48	0.57	0.01	0.55	0.17	-0.5	0.61	0.85	-0.53	0.32	-0.43	0.6	-0.52	0.41	0.53	-0.91		0.05	0.57	-0.71	0.04	0.44	0.37	0.39	-0.13
Deferred Long Term Liab	0.65	0.64	-0.64	0.63	0.66	0.75	0.69	0.21	-0.35	0.65	0.13	-0.33	0.07	-0.74	0.53	0.55	0.74	0.65	-0.1	0.05		0.76	-0.61	0.39	0.84	0.8	0.77	-0.18
Long Term Investments	0.85	0.86	-0.86	0.77	0.86	0.7	0.9	0.23	-0.48	0.87	0.55	-0.5	0.27	-0.83	0.75	0.12	0.93	0.82	-0.55	0.57	0.76		-0.91	0.29	0.91	0.87	0.88	-0.2
Accumulated Depreciation	-0.93	-0.96	0.91	-0.89	-0.96	-0.61	-0.97	-0.31	0.59	-0.95	-0.64	0.63	-0.34	0.89	-0.9	0.01	-0.86	-0.92	0.75	-0.71	-0.61	-0.91		-0.4	-0.88	-0.89	-0.91	0.37
Short Long Term Debt	0.59	0.59	-0.25	0.74	0.58	0.45	0.47	0.31	-0.41	0.55	0.08	-0.41	0.02	-0.57	0.62	0.06	0.51	0.67	-0.29	0.04	0.39	0.29	-0.4		0.51	0.61	0.43	-0.76
Cash And Equivalents	0.88	0.9	-0.85	0.88	0.9	0.69	0.91	0.27	-0.57	0.87	0.48	-0.56	0.18	-0.93	0.81	0.2	0.88	0.9	-0.55	0.44	0.84	0.91	-0.88	0.51		0.97	0.93	-0.32
Net Invested Capital	0.92	0.94	-0.86	0.93	0.92	0.72	0.94	0.35	-0.59	0.88	0.4	-0.6	0.17	-0.96	0.84	0.2	0.89	0.93	-0.53	0.37	0.8	0.87	-0.89	0.61	0.97		0.97	-0.41
Net Working Capital	0.9	0.92	-0.92	0.86	0.9	0.71	0.96	0.31	-0.55	0.86	0.39	-0.57	0.18	-0.94	0.79	0.2	0.88	0.89	-0.53	0.39	0.77	0.88	-0.91	0.43	0.93	0.97		-0.31
Capital Stock	-0.5	-0.51	0.1	-0.68	-0.56	-0.38	-0.35	0.15	0.44	-0.49	0.0	0.18	0.0	0.48	-0.63	-0.02	-0.5	-0.64	0.28	-0.13	-0.18	-0.2	0.37	-0.76	-0.32	-0.41	-0.31

Click cells to compare fundamentals

West Book Value Per Share Historical Pattern

Today, most investors in West Pharmaceutical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various West Pharmaceutical's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's book value per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of West Pharmaceutical book value per share as a starting point in their analysis.

West Pharmaceutical Book Value Per Share

Timeline

The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

Competition

Predict West Pharmaceutical

Book Value Per Share Over Time

West Common Stock Shares Outstanding

Common Stock Shares Outstanding

74.82 Million

At this time, West Pharmaceutical's Common Stock Shares Outstanding is comparatively stable compared to the past year.

In accordance with the recently published financial statements, the book value per share of West Pharmaceutical Services is about 37.1 times. This is 2282.35% lower than that of the Health Care Equipment & Supplies sector and 193.51% higher than that of the Health Care industry. The book value per share for all United States stocks is 98.08% higher than that of the company.

West Book Value Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses West Pharmaceutical's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of West Pharmaceutical could also be used in its relative valuation, which is a method of valuing West Pharmaceutical by comparing valuation metrics of similar companies.

West Pharmaceutical is currently under evaluation in book value per share category among its peers.

West Pharmaceutical ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, West Pharmaceutical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to West Pharmaceutical's managers, analysts, and investors.

Environmental

Governance

Social

West Fundamentals

	Return On Equity	0.18
	Return On Asset	0.0993
	Profit Margin	0.17 %
	Operating Margin	0.23 %
	Current Valuation	16.35 B
	Shares Outstanding	72.3 M
	Shares Owned By Insiders	0.59 %
	Shares Owned By Institutions	97.33 %
	Number Of Shares Shorted	1.37 M
	Price To Earning	40.71 X
	Price To Book	6.16 X
	Price To Sales	5.71 X
	Revenue	2.89 B
	Gross Profit	998.5 M
	EBITDA	743.9 M
	Net Income	492.7 M
	Cash And Equivalents	894.3 M
	Cash Per Share	9.85 X
	Total Debt	302.3 M
	Debt To Equity	0.12 %
	Current Ratio	3.80 X
	Book Value Per Share	37.10 X
	Cash Flow From Operations	653.4 M
	Short Ratio	1.01 X
	Earnings Per Share	6.70 X
	Price To Earnings To Growth	3.92 X
	Target Price	285.01
	Number Of Employees	10.6 K
	Beta	1.09
	Market Capitalization	16.53 B
	Total Asset	3.64 B
	Retained Earnings	3.96 B
	Working Capital	987.7 M
	Current Asset	673.7 M
	Current Liabilities	314.3 M
	Annual Yield	0 %
	Five Year Return	0.36 %
	Net Asset	3.64 B
	Last Dividend Paid	0.81

About West Pharmaceutical Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze West Pharmaceutical Services's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of West Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of West Pharmaceutical Services based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for West Stock Analysis

When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.

Discover investing ideas

Broad Municipals ETFs

Communication Services

Broad Commodities ETFs

World Allocation Funds

Investment Grade ETFs

Corporate Bonds Funds

Utilities - Regulated Electric

Printing and Publishing

Asset Allocation ETFs

Shipbuilding Railroad Equipment

Emerging Markets ETFs

Utilize additional investing modules

AI Portfolio Architect

Global Markets Map

Portfolio Comparator

Analyst Advice

Price Ceiling Movement

Watchlist Optimization

Portfolio Diagnostics

Stock Tickers

Cryptocurrency Center

Price Exposure Probability

Portfolio Backtesting

Portfolio Rebalancing

Investing Opportunities

Fundamentals Comparison

Portfolio File Import

CEOs Directory

Sectors

My Watchlist Analysis

Competition Analyzer

Portfolio Anywhere

Portfolio Optimization

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC